Venture&Growth Archives - Gilde Healthcare

latest news
Venture&Growth

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announced today the appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO) and...
1 December 2021

Gilde Healthcare company Sanifit acquired by Vifor Pharma

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor of vascular calcification in phase 3, developed for the treatment of calcific uremic arteriolopathy (CUA) and peripheral artery disease (PAD) […]

Gilde Healthcare portfolio company Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo

Utrecht, The Netherlands & Basel, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Catherine Moukheibir and Ilise Lombardo as independent members of the company’s Board of Directors. Ms. Moukheibir has extensive experience in finance, capital markets and life sciences, […]

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with...

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert and former Chief Executive Officer of Sage Therapeutics, with more than 25...

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Marketing Authorization Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted,...

Gilde Healthcare company Amphista Therapeutics appoints new chairman, Joshua T. Brumm

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team I am thrilled to welcome someone of...

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced that the U.S. Food and Drug Administration (FDA) has granted the Genio® bilateral hypoglossal nerve stimulation system Breakthrough...

Calypso Biotech announces first patient with Celiac Disease dosed and extension of Series A financing

Single ascending dose administration of CALY-002 to Healthy Volunteers successfully completed Dr Jos G.A. Houbiers MD, PhD joins Calypso Biotech as Chief Medical Officer Fountain Healthcare Partners join existing investors to extend Series A financing Proceeds to accelerate development of CALY-002 for auto-immune diseases including Celiac Disease,...
Loading...
These were all messages
d76b2748b2